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Abstract
We investigated the protective efficacy of two intranasal chitosan (CSN and TM-CSN) adjuvanted H5N1 Influenza vaccines
against highly pathogenic avian Influenza (HPAI) intratracheal and intranasal challenge in a ferret model. Six groups of 6
ferrets were intranasally vaccinated twice, 21 days apart, with either placebo, antigen alone, CSN adjuvanted antigen, or TM-
CSN adjuvanted antigen. Homologous and intra-subtypic antibody cross-reacting responses were assessed. Ferrets were
inoculated intratracheally (all treatments) or intranasally (CSN adjuvanted and placebo treatments only) with clade 1 HPAI A/
Vietnam/1194/2004 (H5N1) virus 28 days after the second vaccination and subsequently monitored for morbidity and
mortality outcomes. Clinical signs were assessed and nasal as well as throat swabs were taken daily for virology. Samples of
lung tissue, nasal turbinates, brain, and olfactory bulb were analysed for the presence of virus and examined for
histolopathological findings. In contrast to animals vaccinated with antigen alone, the CSN and TM-CSN adjuvanted
vaccines induced high levels of antibodies, protected ferrets from death, reduced viral replication and abrogated disease
after intratracheal challenge, and in the case of CSN after intranasal challenge. In particular, the TM-CSN adjuvanted vaccine
was highly effective at eliciting protective immunity from intratracheal challenge; serologically, protective titres were
demonstrable after one vaccination. The 2-dose schedule with TM-CSN vaccine also induced cross-reactive antibodies to
clade 2.1 and 2.2 H5N1 viruses. Furthermore ferrets immunised with TM-CSN had no detectable virus in the respiratory tract
or brain, whereas there were signs of virus in the throat and lungs, albeit at significantly reduced levels, in CSN vaccinated
animals. This study demonstrated for the first time that CSN and in particular TM-CSN adjuvanted intranasal vaccines have
the potential to protect against significant mortality and morbidity arising from infection with HPAI H5N1 virus.
Citation: Mann AJ, Noulin N, Catchpole A, Stittelaar KJ, de Waal L, et al. (2014) Intranasal H5N1 Vaccines, Adjuvanted with Chitosan Derivatives, Protect Ferrets
against Highly Pathogenic Influenza Intranasal and Intratracheal Challenge. PLoS ONE 9(5): e93761. doi:10.1371/journal.pone.0093761
Editor: Nicole M. Bouvier, Mount Sinai School of Medicine, United States of America
Received March 6, 2013; Accepted March 7, 2014; Published May 21, 2014
Copyright:  2014 Mann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by an FP7 EU grant (Grant Agreement number 202083). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: At the time of the study: AJM, NN, AC, RLW were employees of Retroscreen Virology Ltd. JSO was President, Scientific Director of
Retroscreen Virology Ltd. and an employee of Queen Mary College, London. MH and AS were employees of Archimedes Development Limited. KJS, EJBVK, LdW,
GvA and ADMEO were employees of ViroClinics Biosciences BV. ADMEO was chief scientific officer of ViroClinics Biosciences BV. This does not alter the authors’
adherence to all the PLOS ONE policies on sharing data and materials. Additionally as requested by the journal the authors request to also add the following
conflicts that applied at the time of the study: AK was an employee of Evicom, Teddington, United Kingdom. Again, this does not alter the authors’ adherence to
all the PLOS ONE policies on sharing data and materials.
* E-mail: a.mann@retroscreen.com
¤ Current address: Paracelsis Ltd, Nottingham, United Kingdom
Introduction
Avian Influenza (H5N1) continues to present a significant risk to
human health [1],[2],[3],[4], and recent genetic studies of H5
Hemagglutinin (HA) in an H1N1 virus backbone identified only
four mutations in the HA protein were required to facilitate
transmission in the ferret model emphasizing this threat [5].
Antigenic variations amongst H5N1 subtypes alongside the poor
immunogenicity of the HA have both presented vaccine develop-
ers with difficulties [6], [7]. Influenza viruses undergo constant
evolution via antigenic drift, and thus considerable antigenic and
genetic diversity exists among currently circulating H5N1 viruses.
Most H5N1 vaccines that have demonstrated high immunoge-
nicity required co-administration of an adjuvant and administra-
tion by the intramuscular route [8], [9], [10]. According to
published literature, various adjuvanted vaccines have been shown
to be able to reduce mortality in ferret challenge models but have
not a) induced 100% seroconversion, or b) completely prevented
virus replication in the respiratory tract. While protection from
death is the most critical attribute for a pandemic vaccine,
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preventing viral shedding in the respiratory tract is a crucial
additional step to interrupt population level transmission in a well
vaccinated population (at least 60% coverage of healthy individ-
uals for epidemic vaccination) [4],[11].
A ferret model was used in this study as ferrets resemble disease
in humans when infected with Influenza A viruses [12],[13]. This
ferret model is also the gold standard to demonstrate both the
immunogenicity and the protective efficacy of Influenza vaccines
[14],[15],[16],[17],[18].
Chitosan and its derivatives have been widely investigated as
adjuvants for mucosal vaccination and for the intranasal delivery
in particular [19]. Chitosan is a co-polymer of D-glucosamine and
N-acetyl-D-glucosamine in which the amino groups provide a
positive charge in aqueous solution. Chitosan is available
commercially in water-soluble salt forms, such as glutamate and
hydrochloride. Although chitosan salts are largely insoluble above
about pH 6, a number of derivatives with enhanced solubility at
neutral pH are available. One such derivative is trimethyl
chitosan, in which some primary amine groups are replaced with
methyl groups to provide increased solubility in neutral and basic
environments [20].
The purpose of this study, in the ferret viral challenge model,
was to investigate the protective efficacy of ChiSys (Archimedes
Development Limited), a chitosan-based bioadhesive mucosal
delivery system, as an intranasal adjuvant for an inactivated
subunit vaccine containing modified HA and NA (Neuraminidase)
antigens from A/Vietnam/1194/2004 (H5N1). A glutamate salt
form (CSN) and a trimethyl derivative of chitosan (TM-CSN) were
evaluated separately as adjuvants.
Materials and Methods
Viruses and virus reagents
The inactivated Influenza subunit vaccine was prepared from
NIBRG-14, a vaccine seed strain that is a reassortant between
PR8 and A/Vietnam/1194/2004 (Batch No. 1090/10)] that was
kindly supplied by Novartis Vaccines and Diagnostics S.r.l., Italy.
The ferrets were challenged with wild-type Influenza A/Vietnam/
1194/2004 [H5N1] virus. The challenge virus was isolated from
the field and passaged twice in Madin-Darby canine kidney cells
(MDCK, ATCC-CCL-34).
Prior to the study, all ferrets were screened (using the HAI assay)
against the following virus vaccine seed strains (reassortants that
bear the Influenza PRB backbone but retain the HA and NA from
the wild type viruses) were used in the assay: A/Vietnam/1194/
2004 NIBRG-14 [H5N1] with the modified HA, A/Victoria/
210/2009 [H3N2] (NYMCx187), A/California/7/2009 [H1N1]
(NYMCx181). In addition to the above vaccine seed strains, the
wild type virus B/Brisbane/60/2008 was used in the screen. All of
these viruses were supplied by NIBSC, UK.
The vaccine responses in serum were measured with the HAI
assay (Haemagglutination inhibition) by Viroclinics using the
NIBRG-14 virus provided by NIBSC, UK. For HAI and Single
Radial Haemolysis (SRH) assays performed by VisMederi srl., the
viral antigens used were A/Vietnam/1194/2004 [H5N1] as
supplied by NIBSC, A/turkey/Turkey/1/2005 [H5N1] as sup-
plied by NIBSC, and A/Indonesia/5/2005 [H5N1] as supplied by
CBER. For the viral neutralization assays (VN) the live viruses
used were: A/Vietnam/1194/2004 [H5N1] as supplied by
NIBSC, A/turkey/Turkey/1/2005 [H5N1] as supplied by
NIBSC, and A/Indonesia/5/2005 [H5N1] as supplied by the
CDC.
Ferrets & Study Procedures
Thirty-six healthy outbred male ferrets approximately 12
months of age, between 1350 g and 2575 g in weight, were
purchased from a commercial breeder. Animals were housed and
experiments were conducted in compliance with EU directive 86/
609/EEC) and Dutch legislation (Experiments on Animals Act,
1997). The protocol was approved by the independent animal
experimentation ethical review committee of the Netherlands
Vaccine Institute (permit number 201100332). Additional infor-
mation on animal husbandry can be found in the File S1.
All ferrets tested negative for the presence of HAI antibodies
against the challenge virus and recent seasonal strains of Influenza
and Aleutian disease virus.
Three days prior to the first immunisation, the animals had
temperature transponders implanted into the peritoneal cavity
(DST micro-T ultra-small temperature logger; Star-Oddi, Reykja-
vik, Iceland). This device recorded the body temperature of the
animals every 10 minutes. Effect of virus infection on body
temperature was assessed for changes in the temperature of each
ferret post inoculation. Body weights were measured at 1 and 7
days before inoculation and on 1, 2, 3, 4 and 5 days post
inoculation (dpi). Serum was taken days 0, 21, 42, and 49 for
hemagglutination inhibition (HAI), virus neutralization (VN), and
single radial haemolysis (SRH) serology assays. Nasal and throat
swabs were taken on 1, 2, 3, 4 and 5 dpi.
Vaccine formulations
The intranasal vaccine candidates evaluated in the study were
aqueous solutions containing an inactivated NIBRG-14 H5N1
Table 1. Summary of ferret treatment groups and vaccine and adjuvant formulations tested.
Group
Animals per
group Treatment description
Formulation details
(total HA dose)
Route of vaccine
administration
Days of
Immunisations
Route of virus
challenge
1 6 CSN Adjuvanted 0.075 mg/ml
HA+5 mg/ml CSN (15 mg)
Intranasal 0, 21 IN
2 6 CSN Adjuvanted 0.075 mg/ml
HA+5 mg/ml CSN (15 mg)
Intranasal 0, 21 IT
3 6 Unadjuvanted/Antigen alone 0.075 mg/ml HA (15 mg) Intranasal 0, 21 IT
4 6 TM-CSN Adjuvanted 0.075 mg/ml HA+5 mg/ml
TM-CSN (15 mg)
Intranasal 0, 21 IT
5 6 Placebo PBS Intranasal 0, 21 IN
6 6 Placebo PBS Intranasal 0, 21 IT
doi:10.1371/journal.pone.0093761.t001
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subunit antigen, adjuvanted with ChiSys (Archimedes Develop-
ment Limited, UK) utilising either chitosan glutamate (CSN) or
N,N,N-trimethylated chitosan (TM-CSN) as in Table 1. As
controls, antigen alone (unadjuvanted vaccine) chitosan-free
vaccine formulation and placebo [phosphate buffered saline
(PBS)] treatments were also tested.
All materials for dosing to ferrets were supplied by Archimedes.
The inactivated Influenza subunit vaccine HA content was
measured using the SRID assay (Single Radial Immunodiffusion).
Stock material was diluted with PBS or the appropriate CSN/
TM-CSN adjuvant prior to use. The CSN adjuvant utilised
chitosan glutamate 75–90% deacetylated, obtained from FMC
BioPolymer AS, Norway. Stock CSN solutions were prepared in
PBS. TM-CSN adjuvant was 77.7% deacetylated obtained from
KitoZyme, Belgium. Stock TM-CSN solutions were prepared in
ultrapure water. PBS tablets, Sigma, UK were used to prepare
0.01 M PBS, pH 7.4 in ultrapure water as per the manufacturer’s
instructions.
Intranasal Immunisation
Animals were separated into six groups of six ferrets. Animals
were immunised intranasally with 200 ml of the appropriate
treatment divided between both nostrils, according to treatment
assignments in Table 1, on Days 0 and 21 using a positive
displacement automatic pipette with filter tip. As illustrated in
Table 1 the treatment groups consisted of CSN adjuvant +15 mg/
dose (n = 12), TM-CSN +15 mg/dose (n = 6), unadjuvanted +
15 mg/dose (n = 6), and Placebo-PBS (n = 12). The CSN and
Placebo groups were split into two and challenged by either the
intranasal or intratracheal routes, while the TM-CSN and
unadjuvanted treatment groups were only challenged by the
intratracheal route.
Inoculation with homologous H5N1 Influenza: A/
Vietnam/1194/2004 (clade 1)
Four weeks after the last immunisation (day 49), all ferrets were
challenged with wild-type Influenza A/Vietnam/1194/2004
[H5N1] virus. The challenge stock (7.3 log10TCID50/mL) was
diluted in ice-cold PBS to target nominal concentrations of
3.36104 TCID50/mL for intratracheal challenge and 3.3610
5
TCID50/mL for intranasal challenge. The respective virus
concentrations were selected in order to administer a nominal
viral dose of 105 TCID50 to each animal in a 3 mL volume by the
intratracheal route and the 0.3 mL intranasally. After dilution, the
challenge virus was kept on wet ice throughout its usage.
Preparation and administration of the challenge virus inoculums
were performed under BSL3+ conditions. A sample of each
challenge virus dilution was titrated on MDCK cells (ATCC-
CCL-34), as previously described [21]; back titration confirmed
that all ferrets received a total HPAI virus inoculum of 7.56104
TCID50.
Specimens for Viral Analysis
Nasal swabs and throat swabs for viral assays were collected
daily into cold viral stabilisation medium (EMEM containing
bovine serum albumin (fraction V), penicillin, streptomycin,
amphothericin-B, L-glutamine, sodium bicarbonate and Hepes),
aliquoted and stored at 270uC as previously described [21].
After necropsy, cranioventral, craniodorsal, caudoventral and
caudodorsal sections of all lobes of the right lung and the accessory
lobe (pooled per animal), right nasal turbinate and sections of the
right brain and right olfactory bulb from each animal were
collected for quantification of Influenza. All samples were stored at
270uC prior to further processing.
Viral Quantification Assays
Infectious titres were determined by virus titration on MDCK
cells, as previously described [21]. Influenza viral load for nasal
swabs and throat swabs for tissues culture were measured as log
(base 10) tissue culture infectious dose units/mL (log TCID50/mL)
with a lower limit of quantification (LLOQ) of 0.8 log10 TCID50/
mL. Analysis of the turbinates, lung, and olfactory bulb by tissue
culture were expressed as log10TCID50/gram of tissue. The
LLOQ of the tissue samples varied according to the tissue weight.
Serologic Testing
Serum samples collected prior to the first and second
immunisations and prior to inoculation were stored at 220uC.
They were tested against homologous virus as well as clade 2.1 (A/
Indonesia/05/2005) and 2.2 (A/Turkey/Turkey/1/2005) H5N1
viruses using HAI (utilizing both turkey and horse erythroctyes),
VN, and SRH assays.
Sera were analyzed for the presence of anti-HA antibodies
against A/Vietnam/1194/2004 (performed at Viroclinics with an
initial dilution 1:5), A/Indonesia/05/2005 (performed at VisMe-
deri srl, Siena Italy with an initial dilution 1:10), and A/Turkey/
Turkey/1/2005 (also performed at VisMederi srl) by using an
HAI assay with 1% turkey erythrocytes, as described previously
[22]. Additionally the modified HAI method from Stephenson et
al, 2004 was used to measure H5N1 HAI responses in 1% horse
erythrocytes by VisMederi srl (initial dilution of 1:10). Neutralisa-
tion assays were performed at VisMederi srl, as described by
Svindland et al [23] (additional information on the neutralization
assay can be found in the File S1). MDCK-SIAT1 cells were
obtained from ECACC ref. 05071502. The Spearman-Ka¨rber
formula was used to calculate the neutralisation titre of each
sample [24], [25]. Ferrets that had a $4 fold rise in their HAI or
VN titre were identified as seroconverted. Any of Days 21, 42, and
48 could be used when defining seroconversion. Single radial
haemolysis was performed at the University of Siena, Italy, based
on the modified reference method standardised by Schild et al [26]
and performed as described in detail by Svindland et al [23]. A
haemolysis area ,4 mm2 was considered negative, between 4 and
Figure 1. Antibody responses of immunised ferrets to A/Vietnam/1194/2004 (clade 1), A/Indonesia/05/2005 (clade 2.1), & A/Turkey/
Turkey/1/2005 (clade 2.2) H5N1 viruses by HAI (turkey and horse erythrocytes), VN, and SRH assays. All animals were intranasally
immunised on days 0 and 21. Data presented for each of the vaccine groups before and after 1 vaccination (Day 0 and Day 21), 2 vaccinations (Day
42), and just prior to challenge (Day 48). Treatment groups were Placebo (PBS) n= 12; unadjuvanted/antigen alone (0.075 mg/mL HA) n= 6; CSN
adjuvanted vaccine (0.075 mg/mL HA+5 mg/mL CSN) n= 12; & TM-CSN adjuvanted vaccine (0.075 mg/mL HA+5 mg/mL CSN) n = 6. Bars represent
geometric mean group values (horizontal bars) and 6SD (vertical bars). Vaccine responses are as follows: graphs A, D, G, & J are responses to A/
Vietnam/1194/2004, as measured by HAI (turkey erythrocytes), HAI (horse erythrocytes), VN & SRH respectively; B, E, H, & K are responses to A/
Indonesia/05/2005; C, F, I, & L are responses to A/Turkey/Turkey/1/2005. Seroconverting ferrets (threshold represented by blue horizontal dotted line)
were defined as those animals with an equal or greater than 4 fold increase in titre from baseline for the HAI and VN assays. Those that attain an area
of 25 mm2 or more for the SRH assay were defined as seroprotected. Seroprotection levels for the HAI assay were defined as equal or greater than
40HAI (threshold represented by red horizontal dotted line).
doi:10.1371/journal.pone.0093761.g001
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25 mm2 positive but not protective, and greater than 25 mm2 as
positive seroprotective, as per European Medicines Agency & the
Committee for Medicinal Products for Human Use (EMEA
CHMP) guidelines [27]. Positive control serum sample (sheep
hyperimmune sera) was supplied by the National Institute for
Biological Standards and Control, UK).
Pathology
At the time of necropsy, a complete macroscopic post-mortem
examination was performed, the animals were weighed and
abnormalities were recorded. All lung lobes were inspected and
lesions described. The lungs were collected and weighed. The
relative lung weight was calculated as proportion of the body
weight (lung weight/body weight at necroscopy6100). The right
lung was sampled for virology. The left lung and left nasal
turbinates were fixed with 10% neutral buffered formalin for
histopathology. After fixation, sections from the cranial- and
caudal lobes (n = 2 each) and nasal turbinates were embedded in
paraffin and the tissues sections stained with haematoxylin and
eosin and histopathological examination performed as described
elsewhere [28].
Statistical Analysis
Statistical analyses and construction of figures were performed
with GraphPad Prism Software v5.0 (La Jolla, CA). ANOVA and
Fisher’s exact test analyses were two tailed, statistical significance
was set at p = 0.05. Additional information on specific analysis can
be found in the File S1.
Results
Ferrets were observed after each of the vaccinations for general
health. There was no untoward vaccine post-administration
observation noted for the four intranasal treatments.
Vaccination of Ferrets with H5N1 Vaccines and Serologic
Responses
Sera from vaccinated ferrets were tested with HAI, SRH, and
VN assays against the homologous challenge virus (clade 1) as well
as representatives from clade 2.1 and clade 2.2 (Tables S1,S2,& S3
in File S1 respectively). None of the six ferrets vaccinated with
antigen alone (15 mg HA/dose) showed significant serum antibody
titres after two vaccinations by any assay against either homolo-
gous virus or antigenically distinct viruses (Figure 1, & Tables S1,
S2, & S3 in File S1). After a single dose of CSN adjuvanted vaccine
2 out of 12 ferrets seroconverted by HAI (turkey erythrocytes) to
homologous virus, and after two vaccinations 7 out of 12
seroconverted by the HAI (turkey erythrocytes) assay, 7 attained
seroprotective levels in the SRH assay, with 8 out of 12
seroconverting as measured by the VN assay. Of those vaccinated
with the TM-CSN adjuvant 3 out of 6 seroconverted by HAI
(turkey erythrocytes) to homologous virus after one vaccination.
After two vaccinations, 6 out of 6 seroconverted by HAI (turkey
and horse erythrocytes) and VN assays, and all six attained
seroprotective levels measured in the SRH assay.
We assessed cross-clade immunogenicity of the adjuvanted
intranasal vaccines for clade 2.1 (Figures 1B, 1E, 1H, & 1K) and
2.2 (Figures 1C, 1F, 1I, & L) viruses.
Figure 2. Morbidity and mortality in in control and vaccinated
ferrets post challenge with homologous H5N1 HPAI virus. 2A.
Kaplan Meyer survival plot for vaccinated ferrets post challenge. The
following groups were challenged with HPAI virus by the intratracheal
route and the data is shown in 2A: red line = placebo group challenged,
green line = unadjuvanted/antigen alone vaccine group, all other
groups are represented by the black line. 2B.daily percentage weight
change post challenge. Treatment group mean weight changes (%) on
each day post challenge are represented with 6 SEM. 2C. Temperature
change (uC) post challenge. Ferret temperature was monitored every
10 minutes with implantable thermometers allowing analysis of
temperature change from baseline (average of Days 45–48 tempera-
tures for each animal). Treatment group mean temperature changes
every 12 hrs (00:00 and 12:00) are represented with6 SD. The following
groups were challenged with HPAI virus by the intratracheal route and
the data is shown in 2B and 2C: red circle = placebo group challenged,
green squares = unadjuvanted/antigen alone vaccine group, blue
pyramids = CSN adjuvanted vaccine, orange diamonds= TM-CSN adju-
vanted vaccine. The following groups were challenge by the intranasal
route: black diamonds = placebo, and blue circles = CSN adjuvanted
vaccine.
doi:10.1371/journal.pone.0093761.g002
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In animals that received two CSN adjuvanted vaccinations 6
out of 12 animals attained seroprotective levels for A/Turkey/
Turkey/1/2005 by SRH assay, with 2 out of 12 seroconverting by
each of the other assays. Four, 2 and 3 out of the 12 animals
seroconverted to A/Indonesia/05/2005 (clade 2.1) by HAI (turkey
erythrocytes), HAI (horse erythrocytes), and VN assays respec-
tively with 3 ferrets attaining seroprotective levels in the SRH
assay.
In the TM-CSN adjuvant vaccinated ferrets 4 out of 6 ferrets
attained seroprotective levels for A/Indonesia/05/2005 (by SRH
assay). The other serological methods detected seroconversion in
5, 5 and 4 out of 6 animals by HAI (turkey erythrocytes), HAI
(horse erythrocytes), and VN assays respectively. In the TM-CSN
adjuvant vaccinated ferrets 6 out of 6 ferrets attained seroprotec-
tive levels for A/Turkey/Turkey/1/2005 (by SRH assay). The
other serological methods detected seroconversion in 3, 2 and 6
out of 6 animals by HAI (turkey erythrocytes), HAI (horse
erythrocytes), and VN assays respectively.
In addition to using turkey erythrocytes for the HAI assay for
the 3 virus clades, we also used horse erythrocytes. Assays using
horse erythrocytes mostly detected either an equivalent or a lower
number of seroconverting ferrets than when using turkey
erythrocytes. In two cases horse erythrocytes allowed for
identifying seroconversion that was not picked up with turkey
erythrocytes (CSN adjuvanted group after 1 vaccination against
the clade 2.1 and 2.2). This difference is not explained by the
difference in LOD and therefore the seroconversion threshold
definition between the assays. Otherwise the horse blood results
were similar in titre in cases when both assays detected HAI
antibodies.
Protective Efficacy of Intranasal Vaccination vs
Homologous HPAI A/Vietnam/1194/2004 [H5N1] Virus,
with either Lethal Intratracheal Inoculation or Intranasal
Inoculation
Mortality. Intranasal challenge of influenza naı¨ve ferrets
produced virus replication predominantly in the upper respiratory
tract (URT) and central nervous system (CNS) and none of the six
animals had to be euthanised on welfare grounds. In comparison,
the intratracheal route of inoculation resulted in a predominantly
lower respiratory tract infection (LRT) which was associated with a
significantly higher mortality (p,0.05). Thus 5 out of 6 animals
were either found dead or were euthanised prematurely
(Figure 2A). High viral titres in the swabs and tissues, and marked
histopathological changes and weight loss were noted in these
animals.
Vaccination with antigen alone (15 mg HA/dose) did not
protect 2 of 6 animals from premature death. In contrast both
the CSN and TM-CSN adjuvanted vaccines protected all ferrets
from the lethal outcome of intratracheal inoculation. In the groups
inoculated intranasally, including placebo, all animals survived.
Body Weight loss & Body temperature change. Placebo
animals inoculated intratracheally showed more consistent body
weight loss compared to intranasally inoculated ferrets. The CSN
vaccinated animals showed significantly reduced AUC in weight
loss (p,0.05) when compared to both intratracheal and intrana-
sally challenged placebo ferrets (Figure 2B). TM-CSN vaccinated
animals had reduced AUC weight loss but this did not reach
significance (p = 0.09). Both the intracheally inoculated placebo
and antigen only groups exhibited a sharp rise in temperature a
day after challenge that resolved the following day (Figure 2C).
The intranasally inoculated placebo group had a high temperature
from Day 2 that remained elevated until the end of the study.
Vaccination with the CSN adjuvant and antigen reduced the
mean peak temperature rise from baseline (not significant
p = 0.066) compared to placebo when challenged by the intranasal
route. In contrast when challenged by the intratracheal route of
infection, both the CSN and TM-CSN vaccinated ferrets
exhibited significantly reduced mean peak temperature change
compared to the placebo group (p,0.05).
Viral load in the respiratory tract and CNS. Table 2
shows the number of ferrets in each of the vaccine groups that had
culturable virus in either of the URT, LRT, or CNS.
There was no detectable virus in the TM-CSN vaccinated ferret
samples from the URT, LRT, or CNS. In contrast, virus was
Figure 3. Virus Titres in Throat- and Nasal Swabs in control and vaccinated ferrets post challenge. Both throat swabs (3A) and nasal
swabs (3B) were analysed for viral loads by cell culture (log10TCID50/mL) and plotted daily after challenge. Plots contain mean daily mean titres with6
SD for each treatment. The following treatment groups were challenged with HPAI virus by the intratracheal route: red circle = placebo group
challenged, green squares = unadjuvanted/antigen alone vaccine group, blue triangles = CSN adjuvanted vaccine, orange diamonds= TM-CSN
adjuvanted vaccine. The following groups were challenge by the intranasal route: black diamonds=placebo, and blue circles =CSN adjuvanted
vaccine.
doi:10.1371/journal.pone.0093761.g003
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isolated from 3 out of 6 ferrets in the URT (throat swabs), and 2
out of 6 ferrets in the LRT (lung sample) that received CSN
adjuvanted vaccine following intratracheal challenge.
Intranasal CSN adjuvanted vaccinated ferrets had significantly
lower mean AUC of nasal and throat swab titres (mean titres of
each group by day are shown in Figure 3) than placebo (p,0.05),
as well as significantly lower mean AUC of throat swab virus titres
when challenged by the intratracheal route (p,0.05). Those ferrets
that received TM-CSN vaccine and were challenged intratrache-
ally had significantly lower mean AUC virus titre in throat swabs
when compared to placebo (p,0.05).
The mean viral titres of lungs, turbinates, brain and the
olfactory bulb at the day of death from TM-CSN and CSN
treatment groups were all lower than placebo (Figure 4), when
challenged by the intratracheal route. However it should be noted
that possible bias from the timing of death in the ferrets cannot be
discounted for comparisons involving the IT challenged placebo
group and the antigen alone group for viral titres in the lungs,
turbinates, brain and the olfactory bulb. CSN vaccinated animals
had significantly lower mean nasal turbinate virus titres than
placebo when challenge by the intranasal route (p,0.05).
Histopathology. Intratracheal challenge predominantly
damaged the lung tissues (LRT), while intranasal challenge did
not. In contrast intranasal challenge induced severe rhinitis (URT)
in comparison to intratracheal challenge (Figure 5). Overall both
TM-CSN and CSN adjuvanted vaccination of ferrets reduced
LRT histopathological findings compared to placebo. Of those
ferrets that died spontaneously or had to be euthanised prema-
turely all displayed acute severe pneumonia or diffuse alveolar
damage, which was attributed to the challenge virus infection.
None of those animals that were affected by encephalitis died
spontaneously or had to be euthanised prematurely
Figure 4. Virus Titres in Nasal Turbinates, Lungs, Brain, and Olfactory bulb in control and vaccinated ferrets post challenge. On the
day that each ferret was euthanised samples taken from the turbinates (A), lung (B), brain (C), and olfactory bulb (D) were analysed for viral loads by
cell culture (log10TCID50/gram) and plotted as a scatter plot with geometric mean titres for each group. The following groups were challenged with
HPAI virus by the intratracheal route: red circle = placebo group challenged, green squares = unadjuvanted/antigen alone vaccine group, blue
triangles = CSN adjuvanted vaccine, orange diamonds = TM-CSN adjuvanted vaccine. The following groups were challenge by the intranasal route:
black diamonds=placebo, and blue circles =CSN adjuvanted vaccine.
doi:10.1371/journal.pone.0093761.g004
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Figure 5. Histopathology in control and vaccinated ferrets post challenge. Histopathology was performed on ferrets that were euthanised
according to schedule as well as animals euthanized prematurely on welfare groups and any decedents. In those ferrets that were not euthanised
according to the schedule all had acute severe pneumonia or diffuse alveolar damage, which was attributed to the likely cause of death. None of
those animals that were affected by encephalitis had to be euthanised prematurely. Each panel represents: (A) extent of alveolitis, (B) severity of
alveolitis, (C) relative weight of lung, (D) percentage lung affected, and (E) severity of rhinitis.
doi:10.1371/journal.pone.0093761.g005
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Discussion
We evaluated the immunogenicity and protective efficacy of
ChiSys, a chitosan-based bioadhesive mucosal delivery system, as
an intranasal vaccine adjuvant for an inactivated NIBRG-14
H5N1 subunit antigen. This is the first study to our knowledge in
which a chitosan derivative has been used in a ferret Influenza
challenge model.
The mechanism of action of chitosan and derivatives, as an
adjuvant/delivery system for intranasally administered vaccine
antigens, has not been fully elucidated. It is generally accepted that
chitosan functions as a depot to protect and retain subcutaneously
administered antigens at the local site [29] and it is probable that,
as a mucoadhesive, chitosan plays a similar role in the nasal cavity
by delaying mucociliary clearance of administered antigens. What
is known is that solubility, degree of deacetylation, molecular
weight, surface charge, and nature and degree of substitution are
amongst the factors that will determine the effectiveness of the
different chitosan forms as vaccine adjuvants. A glutamate salt
form (CSN) and a trimethyl derivative of chitosan (TM-CSN) were
evaluated in this study.
Vaccination twice with TM-CSN adjuvant (15 mg HA/dose)
induced high serological titres against the vaccine antigen in 100%
of animals with all serological assays, which completely protected
the ferrets from lethal intratracheal challenge and provided
sterilising immunity with no virus replication in URT, LRT,
and CNS samples. Not only did TM-CSN vaccination induce high
levels of antibodies, CSN adjuvanted vaccination also induced
seroconversion and significantly reduced viral shedding and
associated disease when ferrets were challenged by both the lethal
intratracheal route as well as the intranasal route.
Serosurveillance studies in countries where H5N1 is endemic
suggest that there are many people that have been exposed to
H5N1 that have either had subclinical illness or have resolved
their infection without the need to go to hospital [3]. In contrast
the majority of patients seen in hospitals have presented with
severe pneumonia, which had developed several days after
symptom onset [30], [31]. While pneumonia is most frequently
associated with H5N1 infected patients CNS involvement has also
been observed [32].
A comparison of the route of H5N1 inoculation in ferrets and
how it affects pathogenicity has shown that intranasal and
intratracheal inoculation produce different disease profiles [33].
In the present study intratracheal challenge of placebo treated
ferrets resulted in a lethal infection in the majority of animals and
involved predominantly LRT disease with limited URT and CNS
involvement. Intranasal challenge with the same total infectious
titre of virus, although non-lethal, produced severe, predominantly
URT disease with limited spread to the LRT and CNS. The
design of this study included CSN adjuvanted intranasal vaccine
challenged by both inoculation routes to test for protective efficacy
against both disease outcomes. It would have been desirable to
have challenged TM-CSN vaccine and antigen alone (unadju-
vanted) vaccine groups by the intranasal route to evaluate these
vaccines for a non-lethal challenge; however the study was
restricted to 6 groups (36 animals) for ethical reasons.
An ‘‘ideal’’ influenza vaccine would induce long-term immunity
that protects individuals from infection with the homologous virus,
but would also generate cross-protective antibodies against
heterologous strains of the same subtype. It would also allow for
rapid manufacture in the event of a pandemic; require minimal
viral antigen; remain stable at variable temperatures; and be safe,
well-tolerated, and effective when given in a single dose [34]. In
this study the TM-CSN vaccine induced strong cross-clade
reactive antibody responses to H5N1 clades 2.1 and 2.2. The
cross-clade reactive antibodies quantified post-vaccination suggest
that vaccination with TM-CSN would likely protect against an
H5N1 drifted variant challenge. To definitely establish the
protective efficacy in an Influenza naı¨ve ferret challenge model,
the next step for this vaccine could be to challenge vaccinated
animals with a different clade H5N1 virus. As demonstrated by
Govorkova et al., H5N1-vaccinated ferrets that had had prior
infection with epidemic influenza were still protected from
challenge with an H5N1 virus that bore substantial antigenic
differences from the vaccine antigen, even when serology assays
did not detect cross-clade antibodies. [8]. Human subjects are
expected to have had immunological exposure to Influenza within
the first few years after birth [35]. As such it is thought that prior
exposure to related, as well unrelated Influenza strains improves
the response to subsequent antigenic exposure [36],[8]. It would
be ideal if protective antibody responses were established after a
single vaccination thereby reducing the period over which
populations are potentially exposed to virus. Thus a single
vaccination of ferrets with TM-CSN and CSN adjuvants followed
by challenge could yield additional useful information.
Influenza H5N1 vaccines in ferrets have primarily been
delivered by the intramuscular route [9],[10],[37],[38],[39] with
fewer by the intranasal route [40],[41]. Many of these studies have
demonstrated protection from a lethal challenge that was delivered
either intranasally or intratracheally. Many vaccines have not
shown both 100% seroconversion, cross clade seroprotection, as
well as preventing virus replication in URT, LRT and CNS. In
this study, we demonstrated protective immunity from lethal
H5N1 Influenza infection in ferrets following intratracheal
challenge. The TM-CSN adjuvanted vaccine conferred complete
protection in ferrets with no disease or viral shedding in both the
respiratory tract and the CNS. The CSN vaccinated ferrets were
also protected from lethal infection and had reduced viral
replication, clinical signs, and pathological findings.
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